CN102219784A - 可用于抑制chk1的杂芳基脲衍生物 - Google Patents

可用于抑制chk1的杂芳基脲衍生物 Download PDF

Info

Publication number
CN102219784A
CN102219784A CN2011101022112A CN201110102211A CN102219784A CN 102219784 A CN102219784 A CN 102219784A CN 2011101022112 A CN2011101022112 A CN 2011101022112A CN 201110102211 A CN201110102211 A CN 201110102211A CN 102219784 A CN102219784 A CN 102219784A
Authority
CN
China
Prior art keywords
methyl
pyrazine
urea
ylmethoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011101022112A
Other languages
English (en)
Chinese (zh)
Inventor
F·迪亚兹
F·S·法鲁兹
R·霍尔库姆
E·A·凯西奇
H·C·奥伊
A·鲁道夫
F·斯塔彭贝克
E·托尔塞特
J·J·瓜迪诺
K·L·费舍尔
A·W·库克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of CN102219784A publication Critical patent/CN102219784A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CN2011101022112A 2005-03-29 2006-03-29 可用于抑制chk1的杂芳基脲衍生物 Pending CN102219784A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66602605P 2005-03-29 2005-03-29
US60/666,026 2005-03-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2006800101504A Division CN101151259B (zh) 2005-03-29 2006-03-29 可用于抑制chk1的杂芳基脲衍生物

Publications (1)

Publication Number Publication Date
CN102219784A true CN102219784A (zh) 2011-10-19

Family

ID=36677174

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011101022112A Pending CN102219784A (zh) 2005-03-29 2006-03-29 可用于抑制chk1的杂芳基脲衍生物
CN2006800101504A Expired - Fee Related CN101151259B (zh) 2005-03-29 2006-03-29 可用于抑制chk1的杂芳基脲衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2006800101504A Expired - Fee Related CN101151259B (zh) 2005-03-29 2006-03-29 可用于抑制chk1的杂芳基脲衍生物

Country Status (31)

Country Link
US (1) US8093244B2 (cg-RX-API-DMAC7.html)
EP (2) EP1869020B1 (cg-RX-API-DMAC7.html)
JP (2) JP5117374B2 (cg-RX-API-DMAC7.html)
KR (2) KR100912998B1 (cg-RX-API-DMAC7.html)
CN (2) CN102219784A (cg-RX-API-DMAC7.html)
AR (1) AR056645A1 (cg-RX-API-DMAC7.html)
AT (1) ATE490248T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006230337B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0609667A2 (cg-RX-API-DMAC7.html)
CA (1) CA2602199C (cg-RX-API-DMAC7.html)
CR (1) CR9395A (cg-RX-API-DMAC7.html)
CY (1) CY1111240T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006018590D1 (cg-RX-API-DMAC7.html)
DK (1) DK1869020T3 (cg-RX-API-DMAC7.html)
EA (1) EA011287B1 (cg-RX-API-DMAC7.html)
ES (1) ES2356068T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100678T1 (cg-RX-API-DMAC7.html)
IL (1) IL185481A0 (cg-RX-API-DMAC7.html)
MA (1) MA29439B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007012116A (cg-RX-API-DMAC7.html)
NO (1) NO20074944L (cg-RX-API-DMAC7.html)
NZ (1) NZ561458A (cg-RX-API-DMAC7.html)
PL (1) PL1869020T3 (cg-RX-API-DMAC7.html)
PT (1) PT1869020E (cg-RX-API-DMAC7.html)
RS (1) RS51616B (cg-RX-API-DMAC7.html)
SI (1) SI1869020T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN07369A1 (cg-RX-API-DMAC7.html)
TW (1) TWI375559B (cg-RX-API-DMAC7.html)
UA (1) UA92164C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006105262A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200707715B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221367A (en) 1988-08-03 1993-06-22 International Business Machines, Corp. Strained defect-free epitaxial mismatched heterostructures and method of fabrication
NZ575394A (en) 2006-10-20 2012-01-12 Icos Corp Compositions of chk1 inhibitors and cyclodextrin
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CA3013514C (en) 2016-02-04 2021-11-23 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
KR20190130621A (ko) * 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US12404332B2 (en) * 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers
NL2039212B1 (en) 2024-12-02 2026-06-23 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Mitotic cell phase enrichment and ionizing radiation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
US6218109B1 (en) 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
DE69818083T2 (de) 1997-10-06 2004-07-08 Abbott Gmbh & Co. Kg INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001057206A2 (en) 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
WO2001062900A1 (en) 2000-02-25 2001-08-30 The Regents Of The University Of California. Scytonemin and methods of using thereof
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
MXPA03001452A (es) 2000-08-18 2004-05-04 Agouron Pharma Hidroximino-fluorenos heterociclicos y su uso para la inhibicion de las proteinas cinasas.
US20040116497A1 (en) 2001-01-26 2004-06-17 Gabriella Traquandi Chromane derivatives, process for their preparation and their use as antitumor agents
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
JP2004536113A (ja) 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7166639B2 (en) 2001-10-04 2007-01-23 Smithkline Beecham Corporation NF-κB inhibitors
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
AU2003224341A1 (en) 2002-04-26 2003-11-10 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
AU2003243318A1 (en) * 2002-05-29 2003-12-19 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
EA009337B1 (ru) 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
AU2005267185A1 (en) * 2004-06-25 2006-02-02 Icos Corporation Bisarylurea derivatives useful for inhibiting CHK1
CA2679908A1 (en) 2009-09-23 2011-03-23 Shell Internationale Research Maatschappij B.V. Closed loop solvent extraction process for oil sands
CN104407475B (zh) 2014-12-04 2017-04-05 厦门天马微电子有限公司 液晶显示面板

Also Published As

Publication number Publication date
PT1869020E (pt) 2010-12-23
ES2356068T3 (es) 2011-04-04
ZA200707715B (en) 2009-09-30
JP2009227682A (ja) 2009-10-08
WO2006105262A1 (en) 2006-10-05
MX2007012116A (es) 2008-04-08
CY1111240T1 (el) 2015-06-11
TWI375559B (en) 2012-11-01
US8093244B2 (en) 2012-01-10
DK1869020T3 (da) 2011-01-24
UA92164C2 (ru) 2010-10-11
TW200722090A (en) 2007-06-16
CN101151259B (zh) 2011-06-15
NZ561458A (en) 2011-03-31
AU2006230337B2 (en) 2011-10-27
HK1119670A1 (en) 2009-03-13
JP2008535830A (ja) 2008-09-04
BRPI0609667A2 (pt) 2010-04-20
TNSN07369A1 (en) 2008-12-31
CR9395A (es) 2008-03-31
EA200702094A1 (ru) 2008-02-28
EA011287B1 (ru) 2009-02-27
KR20090031459A (ko) 2009-03-25
RS51616B (sr) 2011-08-31
KR20070107178A (ko) 2007-11-06
CA2602199A1 (en) 2006-10-05
US20090143357A1 (en) 2009-06-04
DE602006018590D1 (de) 2011-01-13
EP1869020B1 (en) 2010-12-01
CN101151259A (zh) 2008-03-26
EP1869020A1 (en) 2007-12-26
NO20074944L (no) 2007-10-24
HRP20100678T1 (hr) 2011-02-28
KR100912998B1 (ko) 2009-08-20
IL185481A0 (en) 2008-01-06
ATE490248T1 (de) 2010-12-15
JP5117374B2 (ja) 2013-01-16
AU2006230337A1 (en) 2006-10-05
AR056645A1 (es) 2007-10-17
PL1869020T3 (pl) 2011-05-31
MA29439B1 (fr) 2008-05-02
EP2330105A1 (en) 2011-06-08
CA2602199C (en) 2013-09-10
SI1869020T1 (sl) 2011-02-28

Similar Documents

Publication Publication Date Title
CN100445270C (zh) 嘧啶化合物
CN101583365B (zh) 三嗪衍生物及其治疗应用
US20240368184A1 (en) PIKfyve Inhibitors
NL1026761C2 (nl) 3,5-gedisubstitueerde indazoolverbindingen, farmaceutische preparaten en werkwijzen voor het medieren of remmen van celproliferatie.
EP2150551B1 (de) 2-oxo-3-benzyl-benzoxazol-2-one derivate und verwandte verbindungen als met-kinase inhibitoren zur behandlung von tumoren
EP2483268B1 (de) Pyridinyl-imidazolonderivate zur hemmung von pi3-kinasen
EP2606034A1 (de) Pyrimidinderivate als fak inhibitoren
CN101151259A (zh) 可用于抑制chki的杂芳基脲衍生物
EP2342202A1 (de) Azaindolderivate
JP2015524448A (ja) アルキニルへテロ芳香環化合物及びその応用
WO2010017870A1 (de) Bicyclische triazolderivate zur behandlung von tumoren
WO2007065518A1 (de) Pyridiazinonderivate zur behandlung von tumoren
JP2008535830A5 (cg-RX-API-DMAC7.html)
CN101291927A (zh) 可用作蛋白激酶抑制剂的苯并咪唑
EP2513071B1 (de) Thiazolderivate zur behandlung von krankheiten wie krebs
US20250092032A1 (en) Deoxycytidine kinase inhibitors
KR102133569B1 (ko) 신규한 피롤로[2,3-d]피리미딘-4-온 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
HK1172508A (en) Triazine derivatives and their therapeutical application
HK1119670B (en) Heteroaryl urea derivatives useful for inhibiting chk1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111019